Blog

May 23, 2025, 06:09

Stephen V Liu: Atezolizumab Plus Bevacizumab and Chemotherapy in Metastatic Nonsquamous NSCLC

Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, posted on X:

“Phase III IMpower 151 study Nature Medicine.

305 patients with nsq NSCLC randomized to 1L carboplatin + pemetrexed + bevacizumab +/- atezolizumab. Adding atezolizumab did not significant improve PFS (9.5 vs 7.1m, HR 0.84) or OS (20.7 vs 18.7m, HR 0.93).”

Title: Atezolizumab Plus Bevacizumab and Chemotherapy in Metastatic Nonsquamous NSCLC

Authors: Caicun Zhou, Xiaorong Dong, Gongyan Chen, Zhehai Wang, Xianghua Wu, Yu Yao, Yiping Zhang, Ying Cheng, Hongming Pan, Xiaodong Zhang, Jiuwei Cui, Lifeng Wang, Xi Chen, Xiaoling Li, Ziping Wang, Qiming Wang, Jianxing He, Mengzhao Wang, Iris Yan, Li Qian, Miao Xu, Xiayu Huang, Chun Sun, Jun Cai, Minu K. Srivastava

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Blog

OncoDaily

Blog

Stephen V Liu: Atezolizumab Plus Bevacizumab and Chemotherapy in Metastatic Nonsquamous NSCLC

“Phase III IMpower 151 study Nature Medicine.

305 patients with nsq NSCLC randomized to 1L carboplatin + pemetrexed + bevacizumab +/- atezolizumab. Adding atezolizumab did not significant improve PFS (9.5 vs 7.1m, HR 0.84) or OS (20.7 vs 18.7m, HR 0.93).”